ResMed Inc. Announces Results for the Fourth Quarter of Fiscal Year 2024

• Year-over-year revenue grows 9%, operating profit up 38%, non-GAAP operating profit up 30%
• Operating cash flow of $440 million
• Quarterly dividend increases 10% to $0.53 per share
• Company to host an Investor Day on September 30, 2024

Note: A webcast of ResMed’s conference call will be available at 4:30 p.m. ET today at http://investor.resmed.com

SAN DIEGO, Aug. 01, 2024 (GLOBE NEWSWIRE) -- ResMed Inc. (NYSE: RMD, ASX: RMD) today announced results for its quarter ended June 30, 2024.

Fourth Quarter 2024 Highlights
All comparisons are to the prior year period

• Revenue increased by 9% to $1.2 billion; up 10% on a constant currency basis 
• Gross margin improved 350 bps to 58.5%; non-GAAP gross margin improved 330 bps to 59.1%
• Income from operations increased 38%; non-GAAP income from operations up 30%
• Operating cash flow of $440 million and debt repayments of $300 million
• Diluted earnings per share of $1.98; non-GAAP diluted earnings per share of $2.08

Full Year 2024 Highlights
All comparisons are to the prior year period

• Revenue increased by 11% to $4.7 billion; up 11% on a constant currency basis 
• Gross margin improved 90 bps to 56.7%; non-GAAP gross margin improved 120 bps to 57.7%
• Income from operations increased 17%; non-GAAP income from operations up 21%
• Operating cash flow of $1.4 billion and debt repayments of $0.8 billion
• Diluted earnings per share of $6.92; non-GAAP diluted earnings per share of $7.72

“Our fourth quarter and full-year fiscal year 2024 results demonstrate strong performance across all sectors of our business,” said Mick Farrell, Chairman & CEO of ResMed. “Ongoing patient and customer demand for our best-in-class products and software solutions is incredibly strong, driving solid growth across our devices, masks, and software businesses. The global ResMed team’s focus on operating excellence, ongoing cost discipline, and profitable growth acceleration resulted in gross margin expansion, strong operating leverage, and double-digit growth in bottom-line profitability.

“Nearly 2.5 billion suffer from major sleep health and breathing disorders. As the market leader in these significantly underpenetrated markets, we’re well-positioned as the clear leader to drive increased market penetration, demand generation, and accelerate growth for our businesses. We’re laser-focused on increasing awareness with the fast-growth population of sleep-health-interested consumers, creating virtual pathways that expand access to therapies, while offering a broad portfolio of medical device products, software solutions, and beyond, as we deliver value for all ResMed stakeholders.”

Financial Results and Operating Metrics

Unaudited; $ in millions, except for per share amounts

	Three Months Ended
	June 30, 2024				June 30, 2023				% Change			Constant Currency(A)
Revenue	$	1,223.2			$	1,122.1			9	%		10	%
Gross margin		58.5	%			55.0	%		6
Non-GAAP gross margin(B)		59.1	%			55.8	%		6
Selling, general, and administrative expenses		242.2				240.7			1			1
Research and development expenses		80.9				78.1			3			4
Income from operations		381.2				275.3			38
Non-GAAP income from operations(B)		400.5				307.0			30
Net income		292.2				229.7			27
Non-GAAP net income(B)		306.3				235.5			30
Diluted earnings per share	$	1.98			$	1.56			27
Non-GAAP diluted earnings per share(B)	$	2.08			$	1.60			30

	Twelve Months Ended
	June 30, 2024				June 30, 2023				% Change			Constant Currency(A)
Revenue	$	4,685.3			$	4,223.0			11	%		11	%
Gross margin		56.7	%			55.8	%		2
Non-GAAP gross margin(B)		57.7	%			56.5	%		2
Selling, general, and administrative expenses		917.1				874.0			5			5
Research and development expenses		307.5				287.6			7			8
Income from operations		1,319.9				1,131.9			17
Non-GAAP income from operations(B)		1,478.4				1,224.4			21
Net income		1,021.0				897.6			14
Non-GAAP net income(B)		1,139.3				949.8			20
Diluted earnings per share	$	6.92			$	6.09			14
Non-GAAP diluted earnings per share(B)	$	7.72			$	6.44			20

(A) In order to provide a framework for assessing how our underlying businesses performed, excluding the effect of foreign currency fluctuations, we provide certain financial information on a “constant currency” basis, which is in addition to the actual financial information presented. In order to calculate our constant currency information, we translate the current period financial information using the foreign currency exchange rates that were in effect during the previous comparable period. However, constant currency measures should not be considered in isolation or as an alternative to U.S. dollar measures that reflect current period exchange rates, or to other financial measures calculated and presented in accordance with U.S. GAAP.
(B) See the reconciliation of non-GAAP financial measures in the table at the end of the press release. 

Discussion of Fourth Quarter Results
All comparisons are to the prior year period unless otherwise noted

• Revenue grew by 10 percent on a constant currency basis, driven by increased demand for our sleep devices and masks portfolio, as well as strong growth across our Software as a Service business.
  • Revenue in the U.S., Canada, and Latin America, excluding Software as a Service, grew by 10 percent.
  • Revenue in Europe, Asia, and other markets, excluding Software as a Service, grew by 8 percent on a constant currency basis.
  • Software as a Service revenue increased by 10 percent, reflecting continued organic growth in our SaaS portfolio.
• Gross margin increased by 350 basis points mainly due to reduced freight and manufacturing cost improvements, an increase in average selling prices as well as favorable product mix. Non-GAAP gross margin increased by 330 basis points due to the same factors.
• Selling, general, and administrative expenses increased by 1 percent on a constant currency basis. SG&A expenses improved to 19.8 percent of revenue in the quarter, compared with 21.5 percent in the same period of the prior year. The modest increase in SG&A expenses reflects cost management initiatives implemented during the December quarter.
• Income from operations increased by 38 percent, and non-GAAP income from operations increased by 30 percent.
• Net income for the quarter was $292 million and diluted earnings per share was $1.98. Non-GAAP net income increased by 30 percent to $306 million, and non-GAAP diluted earnings per share increased by 30 percent to $2.08, predominantly attributable to strong sales and gross margin improvement as well as modest growth in operating expenses.
• Operating cash flow for the quarter was $440 million, compared to net income in the current quarter of $292 million and non-GAAP net income of $306 million.
• During the quarter, we paid $71 million in dividends and repurchased 232,000 shares for consideration of $50 million as part of our ongoing capital management.

Other Business and Operational Highlights

• Supported the presentation of 39 clinical research abstracts at the annual American Thoracic Society (26 abstracts) and SLEEP (13 abstracts) conferences, demonstrating the breadth and depth of ResMed’s leadership in generating and analyzing real-world evidence in support of better clinical and patient outcomes. Research focused on a variety of topics including the increasing prevalence of Obstructive Sleep Apnea (OSA), the economic benefits of treating OSA, and the relationship between OSA and depression in women.

Dividend program
The ResMed board of directors today declared a quarterly cash dividend of $0.53 per share. The dividend will have a record date of August 15, 2024, payable on September 19, 2024. The dividend will be paid in U.S. currency to holders of ResMed’s common stock trading on the New York Stock Exchange. Holders of CHESS Depositary Interests (“CDIs”) trading on the Australian Securities Exchange will receive an equivalent amount in Australian currency, based on the exchange rate on the record date, and reflecting the 10:1 ratio between CDIs and NYSE shares. The ex-dividend date will be August 14, 2024, for common stockholders and for CDI holders. ResMed has received a waiver from the ASX’s settlement operating rules, which will allow ResMed to defer processing conversions between its common stock and CDI registers from August 14, 2024, through August 15, 2024, inclusive. 

Webcast details
ResMed will discuss its fourth quarter fiscal year 2024 results on its webcast at 1:30 p.m. U.S. Pacific Time today. The live webcast of the call can be accessed on ResMed’s Investor Relations website at investor.resmed.com. Please go to this section of the website and click on the icon for the “Q4 2024 Earnings Webcast” to register and listen to the live webcast. A replay of the earnings webcast will be accessible on the website and available approximately two hours after the live webcast. In addition, a telephone replay of the conference call will be available approximately three hours after the webcast by dialing +1 877-660-6853 (U.S.) or +1 201-612-7415 (outside U.S.) and entering the passcode 13747201. The telephone replay will be available until August 15, 2024.

About ResMed
At ResMed (NYSE: RMD, ASX: RMD) we pioneer innovative solutions that treat and keep people out of the hospital, empowering them to live healthier, higher-quality lives. Our digital health technologies and cloud-connected medical devices transform care for people with sleep apnea, COPD, and other chronic diseases. Our comprehensive out-of-hospital software platforms support the professionals and caregivers who help people stay healthy in the home or care setting of their choice. By enabling better care, we improve quality of life, reduce the impact of chronic disease, and lower costs for consumers and healthcare systems in more than 140 countries. To learn more, visit ResMed.com and follow @ResMed.

Safe harbor statement
Statements contained in this release that are not historical facts are “forward-looking” statements as contemplated by the Private Securities Litigation Reform Act of 1995. These forward-looking statements – including statements regarding ResMed’s projections of future revenue or earnings, expenses, new product development, new product launches, new markets for its products, the integration of acquisitions, our supply chain, domestic and international regulatory developments, litigation, tax outlook, and the expected impact of macroeconomic conditions of our business – are subject to risks and uncertainties, which could cause actual results to materially differ from those projected or implied in the forward-looking statements. Additional risks and uncertainties are discussed in ResMed’s periodic reports on file with the U.S. Securities & Exchange Commission. ResMed does not undertake to update its forward-looking statements.

Condensed Consolidated Statements of Operations
(Unaudited; $ in thousands, except for per share amounts)

	Three Months Ended								Twelve Months Ended
	June 30, 2024				June 30, 2023				June 30, 2024				June 30, 2023
Net revenue	$	1,223,195			$	1,122,057			$	4,685,297			$	4,222,993
Cost of sales		499,681				496,276				1,982,769				1,836,935
Amortization of acquired intangibles(1)		7,987				8,395				32,963				30,396
Masks with magnets field safety notification expenses(1)		—				—				6,351				—
Astral field safety notification expenses(1)		—				—				7,911				—
Total cost of sales	$	507,668			$	504,671			$	2,029,994			$	1,867,331
Gross profit	$	715,527			$	617,386			$	2,655,303			$	2,355,662
Selling, general, and administrative		242,187				240,687				917,136				874,003
Research and development		80,861				78,144				307,525				287,642
Amortization of acquired intangibles(1)		11,262				12,319				46,521				42,020
Restructuring expenses(1)		—				9,177				64,228				9,177
Acquisition related expenses(1)		—				1,792				—				10,949
Total operating expenses	$	334,310			$	342,119			$	1,335,410			$	1,223,791
Income from operations	$	381,217			$	275,267			$	1,319,893			$	1,131,871
Other income (expenses), net:
Interest expense, net	$	(5,920	)		$	(14,943	)		$	(45,708	)		$	(47,379	)
Gain (loss) attributable to equity method investments		868				(2,228	)			(1,848	)			(7,265	)
Gain on equity investments(1)		(15,473	)			(1,583	)			(4,045	)			9,922
Gain on insurance recoveries(1)		—				20,227				—				20,227
Other, net		(2,960	)			61				(3,494	)			(5,712	)
Total other income (expenses), net		(23,485	)			1,534				(55,095	)			(30,207	)
Income before income taxes	$	357,732			$	276,801			$	1,264,798			$	1,101,664
Income taxes		65,495				47,137				243,847				204,108
Net income	$	292,237			$	229,664			$	1,020,951			$	897,556
Basic earnings per share	$	1.99			$	1.56			$	6.94			$	6.12
Diluted earnings per share	$	1.98			$	1.56			$	6.92			$	6.09
Non-GAAP diluted earnings per share(1)	$	2.08			$	1.60			$	7.72			$	6.44
Basic shares outstanding		146,915				147,015				147,021				146,765
Diluted shares outstanding		147,533				147,554				147,550				147,455

(1) See the reconciliation of non-GAAP financial measures in the table at the end of the press release.

Condensed Consolidated Balance Sheets
(Unaudited; $ in thousands)

	June 30, 2024				June 30, 2023
Assets
Current assets:
Cash and cash equivalents	$	238,361			$	227,891
Accounts receivable, net		837,275				704,909
Inventories		822,250				998,012
Prepayments and other current assets		459,833				437,018
Total current assets	$	2,357,719			$	2,367,830
Non-current assets:
Property, plant, and equipment, net	$	548,025			$	537,856
Operating lease right-of-use assets		151,121				127,955
Goodwill and other intangibles, net		3,327,959				3,322,640
Deferred income taxes and other non-current assets		487,570				395,427
Total non-current assets	$	4,514,675			$	4,383,878
Total assets	$	6,872,394			$	6,751,708
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable	$	237,728			$	150,756
Accrued expenses		377,678				365,660
Operating lease liabilities, current		25,278				21,919
Deferred revenue		152,554				138,072
Income taxes payable		107,517				72,224
Short-term debt		9,900				9,902
Total current liabilities	$	910,655			$	758,533
Non-current liabilities:
Deferred revenue	$	137,343			$	119,186
Deferred income taxes		79,339				90,650
Operating lease liabilities, non-current		141,444				116,853
Other long-term liabilities		42,257				68,166
Long-term debt		697,313				1,431,234
Long-term income taxes payable		—				37,183
Total non-current liabilities	$	1,097,696			$	1,863,272
Total liabilities	$	2,008,351			$	2,621,805
Stockholders’ equity
Common stock	$	588			$	588
Additional paid-in capital		1,896,604				1,772,083
Retained earnings		4,991,647				4,253,016
Treasury stock		(1,773,267	)			(1,623,256	)
Accumulated other comprehensive income		(251,529	)			(272,528	)
Total stockholders’ equity	$	4,864,043			$	4,129,903
Total liabilities and stockholders’ equity	$	6,872,394			$	6,751,708

Condensed Consolidated Statements of Cash Flows
(Unaudited; $ in thousands)

	Three Months Ended								Twelve Months Ended
	June 30, 2024				June 30, 2023				June 30, 2024				June 30, 2023
Cash flows from operating activities:
Net income	$	292,237			$	229,664			$	1,020,951			$	897,556
Adjustment to reconcile net income to cash provided by operating activities:
Depreciation and amortization		43,677				46,760				176,870				165,156
Amortization of right-of-use assets		11,077				8,440				39,339				32,406
Stock-based compensation costs		21,392				19,927				80,184				71,142
(Gain) loss attributable to equity method investments, net of dividends received		(868	)			5,102				1,848				10,138
(Gain) loss on equity investments		15,473				1,584				4,045				(9,922	)
Non-cash restructuring expenses		—				9,177				33,239				9,177
Gain on insurance recoveries		—				(20,227	)			—				(20,227	)
Changes in operating assets and liabilities:
Accounts receivable, net		(57,523	)			(18,059	)			(134,278	)			(106,511	)
Inventories, net		8,910				6,257				172,203				(248,833	)
Prepaid expenses, net deferred income taxes and other current assets		(16,237	)			(51,518	)			(115,213	)			(138,125	)
Accounts payable, accrued expenses, income taxes payable and other		121,975				330				122,072				31,342
Net cash provided by operating activities	$	440,113			$	237,437			$	1,401,260			$	693,299
Cash flows from investing activities:
Purchases of property, plant, and equipment		(24,881	)			(34,449	)			(99,460	)			(119,672	)
Patent registration and acquisition costs		(1,442	)			(4,285	)			(15,396	)			(14,328	)
Business acquisitions, net of cash acquired		(19,697	)			(1,524	)			(133,464	)			(1,012,749	)
Purchases of investments		(3,073	)			(2,500	)			(12,765	)			(32,229	)
Proceeds from exits of investments		750				—				1,000				3,937
(Payments) / proceeds on maturity of foreign currency contracts		1,833				(3,765	)			(9,699	)			15,196
Net cash used in investing activities	$	(46,510	)		$	(46,523	)		$	(269,784	)		$	(1,159,845	)
Cash flows from financing activities:
Proceeds from issuance of common stock, net		27,696				23,493				53,094				49,142
Purchases of treasury stock		(50,004	)			—				(150,011	)			—
Taxes paid related to net share settlement of equity awards		(421	)			(334	)			(8,757	)			(30,631	)
Payments of business combination contingent consideration		—				(2,045	)			(1,293	)			(2,361	)
Proceeds from borrowings, net of borrowing costs		—				—				105,000				1,070,000
Repayment of borrowings		(300,000	)			(145,000	)			(835,000	)			(405,000	)
Dividends paid		(70,553	)			(64,705	)			(282,320	)			(258,276	)
Net cash (used in) / provided by financing activities	$	(393,282	)		$	(188,591	)		$	(1,119,287	)		$	422,874
Effect of exchange rate changes on cash	$	130			$	(2,326	)		$	(1,719	)		$	(2,147	)
Net increase / (decrease) in cash and cash equivalents		451				(3	)			10,470				(45,819	)
Cash and cash equivalents at beginning of period		237,910				227,894				227,891				273,710
Cash and cash equivalents at end of period	$	238,361			$	227,891			$	238,361			$	227,891

Reconciliation of Non-GAAP Financial Measures
(Unaudited; $ in thousands, except for per share amounts)

The measures “non-GAAP gross profit” and “non-GAAP gross margin” exclude amortization expense from acquired intangibles and restructuring expense related to cost of sales and are reconciled below:

	Three Months Ended								Twelve Months Ended
	June 30, 2024				June 30, 2023				June 30, 2024				June 30, 2023
Revenue	$	1,223,195			$	1,122,057			$	4,685,297			$	4,222,993
GAAP cost of sales	$	507,668			$	504,671			$	2,029,994			$	1,867,331
Less:Amortization of acquired intangibles(A)		(7,987	)			(8,395	)			(32,963	)			(30,396	)
Less: Masks with magnets field safety notification expenses(A)		—				—				(6,351	)			—
Less: Astral field safety notification expenses(A)		—				—				(7,911	)			—
Non-GAAP cost of sales	$	499,681			$	496,276			$	1,982,769			$	1,836,935
GAAP gross profit	$	715,527			$	617,386			$	2,655,303			$	2,355,662
GAAP gross margin		58.5	%			55.0	%			56.7	%			55.8	%
Non-GAAP gross profit	$	723,514			$	625,781			$	2,702,528			$	2,386,058
Non-GAAP gross margin		59.1	%			55.8	%			57.7	%			56.5	%

The measure “non-GAAP income from operations” is reconciled with GAAP income from operations below:

	Three Months Ended						Twelve Months Ended
	June 30, 2024			June 30, 2023			June 30, 2024			June 30, 2023
GAAP income from operations	$	381,217		$	275,267		$	1,319,893		$	1,131,871
Amortization of acquired intangibles—cost of sales(A)		7,987			8,395			32,963			30,396
Amortization of acquired intangibles—operating expenses(A)		11,262			12,319			46,521			42,020
Restructuring(A)		—			9,177			64,228			9,177
Masks with magnets field safety notification expenses(A)		—			—			6,351			—
Astral field safety notification expenses(A)		—			—			7,911			—
Acquisition-related expenses(A)		—			1,792			483			10,949
Non-GAAP income from operations	$	400,466		$	306,950		$	1,478,350		$	1,224,413

Reconciliation of Non-GAAP Financial Measures
(Unaudited; $ in thousands, except for per share amounts)

The measures “non-GAAP net income” and “non-GAAP diluted earnings per share” are reconciled with GAAP net income and GAAP diluted earnings per share in the table below:

	Three Months Ended								Twelve Months Ended
	June 30, 2024				June 30, 2023				June 30, 2024				June 30, 2023
GAAP net income	$	292,237			$	229,664			$	1,020,951			$	897,556
Amortization of acquired intangibles—cost of sales(A)		7,987				8,395				32,963				30,396
Amortization of acquired intangibles—operating expenses(A)		11,262				12,319				46,521				42,020
Restructuring expenses(A)		—				9,177				64,228				9,177
Masks with magnets field safety notification expenses(A)		—				—				6,351				—
Astral field safety notification expenses(A)		—				—				7,911				—
Acquisition-related expenses(A)		—				1,792				483				10,949
Gain on insurance recoveries(A)		—				(20,227	)			—				(20,227	)
Income tax effect on non-GAAP adjustments(A)		(5,145	)			(5,631	)			(40,114	)			(20,114	)
Non-GAAP net income(A)	$	306,341			$	235,489			$	1,139,294			$	949,757
GAAP diluted shares outstanding		147,533				147,554				147,550				147,455
GAAP diluted earnings per share	$	1.98			$	1.56			$	6.92			$	6.09
Non-GAAP diluted earnings per share(A)	$	2.08			$	1.60			$	7.72			$	6.44

(A) ResMed adjusts for the impact of the amortization of acquired intangibles, restructuring expenses, field safety notification expenses, acquisition-related expenses, gain on insurance recoveries, and associated tax effects from their evaluation of ongoing operations, and believes that investors benefit from adjusting these items to facilitate a more meaningful evaluation of current operating performance.

ResMed believes that non-GAAP diluted earnings per share is an additional measure of performance that investors can use to compare operating results between reporting periods. ResMed uses non-GAAP information internally in planning, forecasting, and evaluating the results of operations in the current period and in comparing it to past periods. ResMed believes this information provides investors better insight when evaluating ResMed’s performance from core operations and provides consistent financial reporting. The use of non-GAAP measures is intended to supplement, and not to replace, the presentation of net income and other GAAP measures. Like all non-GAAP measures, non-GAAP earnings are subject to inherent limitations because they do not include all the expenses that must be included under GAAP.

Revenue by Product and Region
(Unaudited; $ in millions, except for per share amounts)

	Three Months Ended
	June 30, 2024		(A)	June 30, 2023		(A)	% Change			Constant Currency(B)
U.S., Canada, and Latin America
Devices	$	406.2		$	387.2		5	%
Masks and other		321.2			273.7		17
Total U.S., Canada and Latin America	$	727.4		$	660.9		10
Combined Europe, Asia, and other markets
Devices	$	228.8		$	215.2		6	%		8	%
Masks and other		115.0			107.4		7			9
Total Combined Europe, Asia and other markets	$	343.9		$	322.6		7			8
Global revenue
Total Devices	$	635.1		$	602.4		5	%		6	%
Total Masks and other		436.2			381.0		14			15
Total Sleep and Respiratory Care	$	1,071.3		$	983.5		9			9
Software as a Service		151.9			138.6		10			10
Total	$	1,223.2		$	1,122.1		9			10

	Twelve Months Ended
	June 30, 2024		(A)	June 30, 2023		(A)	% Change			Constant Currency(B)
U.S., Canada, and Latin America
Devices	$	1,522.8		$	1,444.4		5	%
Masks and other		1,199.8			1,039.0		15
Total U.S., Canada and Latin America	$	2,722.6		$	2,483.4		10
Combined Europe, Asia, and other markets
Devices	$	921.3		$	826.3		11	%		10	%
Masks and other		457.4			415.3		10			8
Total Combined Europe, Asia and other markets	$	1,378.6		$	1,241.6		11			10
Global revenue
Total Devices	$	2,444.0		$	2,270.7		8	%		7	%
Total Masks and other		1,657.2			1,454.3		14			13
Total Sleep and Respiratory Care	$	4,101.2		$	3,725.0		10			10
Software as a Service		584.1			498.0		17			17
Total	$	4,685.3		$	4,223.0		11			11

(A) Totals and subtotals may not add due to rounding.

(B) In order to provide a framework for assessing how our underlying businesses performed excluding the effect of foreign currency fluctuations, we provide certain financial information on a “constant currency basis,” which is in addition to the actual financial information presented. In order to calculate our constant currency information, we translate the current period financial information using the foreign currency exchange rates that were in effect during the previous comparable period. However, constant currency measures should not be considered in isolation or as an alternative to U.S. dollar measures that reflect current period exchange rates, or to other financial measures calculated and presented in accordance with U.S. GAAP.

For investors	For media
+1 858-836-5000	+1 619-510-1281
investorrelations@resmed.com	news@resmed.com